Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Gman620on Apr 04, 2023 4:12pm
270 Views
Post# 35379574

RE:RE:RE:RE:Example of a jv deal

RE:RE:RE:RE:Example of a jv deal Well, since no one really answered the question. I asked ChatGPT the general question:

What percentage of promising cancer treatments actually get commercialized?

>

The percentage of promising cancer treatments that actually get commercialized can vary widely depending on various factors such as the type of cancer, the stage of development of the treatment, the success rate in clinical trials, and the regulatory and financial hurdles to getting a treatment approved and to market.

It is difficult to give a precise figure, but according to a report by the Pharmaceutical Research and Manufacturers of America (PhRMA), only about 12% of cancer drugs that enter clinical trials are ultimately approved by the US Food and Drug Administration (FDA) for commercialization. However, this figure only represents drugs that make it to clinical trials, and many more treatments never make it that far due to lack of funding, poor results in preclinical studies, or other reasons.

It's worth noting that even after a treatment is approved by the FDA, it can take several more years and significant investment to bring it to market and make it widely available to patients. Additionally, not all promising cancer treatments are developed by pharmaceutical companies; some may be developed by academic researchers or small biotech firms that may face additional challenges in commercializing their products.


<< Previous
Bullboard Posts
Next >>